Abstract YO19
Case summary
Recent studies have shown evidence of cross-lineage transdifferentiation of B-cell lymphomas, such as low-grade FL and CLL/SLL,to histiocytic and dendritic cell sarcomas, but the clonal relationship between the 2 neoplasms is still unclear. Here, we report the morphologic, molecular and cytogenetic analysis of a unique case of CLL/SLL associated with indeterminate dendritic cell tumor and possibly a hybrid lymphodendritic cell neoplasm , using immunohistochemistry, electron microscopy, in situ hybridization and FISH.A 48-year-old Chinese female presented with left upper neck swelling. Blood examination revealed lymphocytosis.Microscopic examinations showed the lymph node has effaced architecture, and has a very complicated, variegated appearance with three distinct components. The first component contained small lymphocytes, prolymphocytes and paraimmunoblasts, showing typical CLL/SLL immunophenotype, with ZAP-70 positive and EBV negative. The second component contained nodular aggregates of large pink cells with abundant eosinophilic cytoplasm and deeply grooved nuclei, showing immunophenotype of indeterminate dendritic cell tumor and EBV positive. The third component had intermediate morphologic features between lymphoid cells and dendritic cells characteristics, a bit reminiscent of anaplastic large cell lymphoma, but expressed some B cell markers PAX5 and OCT2, as well as dendritic/histiocytic markers CD1a, CD68, Fascin, and Lysozyme, and was diffusely EBV positive. Electron microscopy revealed the cells in the third component had short and thick bulges like dendritic cell. FISH analysis using CLL probes showed identical deletion 17p13.1, deletion 11q22.3, and deletion 13q14.3 in all 3 components. Sharing of CD5 and OCT2 expression and identical cytogenetic abnormality in all 3 components suggest a common clonal origin for the three components.Our study provides evidence for transdifferentiation of CLL/SLL to dendritic cell tumor possibly via the intermediate linklymplymphodendritic cell neoplasm, and suggests that EBV may play a role in this phenomenon.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract